Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance
Publication in refereed journal

替代計量分析
.

其它資訊
摘要Background and Aims:
Previous studies suggested spontaneous seroclearance of hepatitis B surface antigen (HBsAg) was still associated with an increased risk of hepatocellular carcinoma (HCC), in patients >= 50 years of age. This study aimed to evaluate the risk of HCC after HBsAg seroclearance and the impact of gender on HCC.
Methods:
All chronic hepatitis B patients under medical care in Hospital Authority, Hong Kong who had cleared HBsAg between January 2000 and August 2016 were identified. The age of the patient at HBsAg seroclearance, gender, and subsequent development of HCC were analyzed.
Results:
A total of 4,568 patients with HBsAg seroclearance were identified; 793 (17.4%) were treated by nucleos(t)ide analogues and 60 (1.3%) had received interferon treatment. At a median (interquartile range) follow-up of 3.4 (1.5-5.0) years, 54 patients developed HCC; cumulative incidences of HCC at 1, 3 and 5 years were 0.9%, 1.3% and 1.5%, respectively. Age above 50 years (adjusted hazard ratio 4.31, 95% confidence interval 1.72-10.84; p = 0.002) and male gender (2.47, 1.24-4.91; p = 0.01) were two independent risk factors of HCC. Female patients aged <= 50 years (n = 545) had zero risk of HCC within 5 years of follow-up. Male patients aged <= 50 years (n = 769), female patients aged >50 years (n = 1,149) and male patients aged >50 years (n = 2,105) had a 5-year cumulative incidence of HCC 0.7%, 1.0% and 2.5%, respectively. Similar findings were observed in patients with spontaneous and antiviral treatment-induced HBsAg seroclearance.
Conclusions:
Female patients aged 50 years or below have zero risk of HCC after HBsAg seroclearance, whereas female patients aged above 50 years and all male patients are still at risk of HCC.
Lay summary:
We investigated 4,568 patients with hepatitis B surface antigen (HBsAg) seroclearance. Female patients aged 50 years or below have zero risk of hepatocellular carcinoma (HCC) after HBsAg seroclearance, whereas female patients aged above 50 years and all male patients are still at risk of HCC.
著者Yip TCF, Chan HLY, Wong VWS, Tse YK, Lam KLY, Wong GLH
期刊名稱Journal of Hepatology
出版年份2017
月份11
卷號67
期次5
出版社ELSEVIER SCIENCE BV
頁次902 - 908
國際標準期刊號0168-8278
電子國際標準期刊號1600-0641
語言英式英語
關鍵詞Age,Gender,Antiviral therapy,HBsAg seroclearance,HBsAg seroreversion,HCC,HBV,Sustained response
Web of Science 學科類別Gastroenterology & Hepatology;Gastroenterology & Hepatology

上次更新時間 2020-15-08 於 01:47